Tizona Appoints Christine O’Brien as Chief Executive Officer -- Transaction with Gilead Sciences Closed -- -- Tizona Advances TTX-080, a Novel Anti-HLA-G Antibody, with First Patients Treated in Phase I Study – SOUTH SAN FRANCISCO, Calif., Sept. 15, 2020 ...

Tizona to Present at The Cowen and Company 40th Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, announced today...

Tizona Elects Daniel K. Spiegelman to Its Board of Directors SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced the appointment of Daniel K. Spiegelman to its Board...